Study #2025-1635
BAF-FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, And Preliminary Efficacy Of LY4152199, A B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody, In Adult Participants With Previously Treated B-Cell Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
LY4152199 - IV
Description
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell
Study phase:
Phase I
Physician name:
Paolo Strati
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.